Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 3111
Original Agreement January 2008, the Company entered into a U.S. License Agreement for OnconaseÂ® with Par Pharmaceutical, Inc. Under the terms of the License Agreement, Strativa Pharmaceuticals, the proprietary products division of Par, received exclusive marketing, sales and distribution rights to OnconaseÂ® for the treatment of cancer in the United States and its territories. The Company retained all rights and obligations for product manufacturing, clinical development and obtaining regulatory approvals, as well as all rights for those non-U.S. jurisdictions in which the Company has not currently granted any such rights or obligations to third parties. The Company received a cash payment of $ upon the signing of the License Agreement.
IPSCIO Record ID: 368522
– an exclusive license under the Licensor Patents and under any and all applicable Regulatory Approvals in the Field to promote, market, have marketed, distribute, sell, offer for sale and otherwise Commercialize Product in the Field in the Territory and to do such other things necessary to comply with Licensees obligations under this Agreement.
– as further provided, in order to protect the Product in the Field, an exclusive license to enforce the Licensor Patents against any potential Third Party infringement that could reasonably be expected to adversely affect the Commercialization or value of the Product in the Territory.
Licensor grants an exclusive license in the Field in the Territory, without the right to sublicense, under the Trademark and each Trade Name that has obtained or hereafter obtains Regulatory Approval for use in connection with the Product, to promote, market, offer for sale, sell and have sold Product in the Field in the Territory.
Ranpirnase means the active pharmaceutical ingredient, which may be obtained from natural sources or a recombinant source. For the sake of clarity, sequence variants, and fusion proteins and conjugates that incorporate Ranpirnase, are expressly excluded, but various formulations of the active pharmaceutical ingredient described.
Trademark means United States Trademark Reg. No. 1,651,885, covering ONCONASE as applied to pharmaceuticals; namely, cancer-treating drugs.
ONCONASE is a first-in-class product candidate based on Licensor's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.
The Field means all uses for cancer in humans.
IPSCIO Record ID: 203